Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial of pazopanib hydrochloride in advanced angiosarcoma has completed and results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Pazopanib hydrochloride (pazopanib)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2022-08-19